
Please try another search
On Wednesday, Cidara Therapeutics (NASDAQ:CDTX) received an upgraded stock rating from Neutral to Buy by H.C. Wainwright, accompanied by a new price target set at $24.00. The upgrade reflects a...
Investing.com - Cidara Therapeutics Inc (NASDAQ: CDTX) reported second quarter EPS of $-20.650, $20.51 worse than the analyst estimate of $-0.140. Revenue for the quarter came in at $300K versus the...
SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc...
Cidara Therapeutics (NASDAQ:CDTX) has filed for up to 16,800,000 share offering by selling stockholders.
SAN DIEGO, CA – Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company specializing in the development of biological products, announced significant corporate updates following its...
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics (NASDAQ:CDTX), Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate...
In a recent transaction, Jeffrey Stein, President and CEO of Cidara Therapeutics, Inc. (NASDAQ:CDTX), has increased his stake in the company by purchasing shares valued at a total of $105,680. The...
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC)...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review